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 Introduction
 Many of the effects of fiber on stool output arise from 
their degradation in the colon by resident bacterial flora. 
The main products of fiber fermentation are short-chain 
fatty acids (SCFAs) including acetate, propionate and bu-
tyrate, which represent the major anions in the colon  [1] . 
Most of the SCFAs that are produced are likely to be ab-
sorbed by the colonic epithelium  [2] and are metabolized 
in the epithelium (butyrate), the liver (propionate) or pe-
ripheral tissues (acetate). The transepithelial transport of 
SCFAs is associated with an increase of sodium absorp-
tion from the colon which results in increased water ab-
sorption from the lumen  [3–5] . This effect may be par-
ticularly important in acute diarrheal diseases where in-
creased purging and associated reduced food intake 
might deplete the colon of SCFAs leading to colonic dys-
function  [6, 7] . Thus, luminal SCFA levels in the colon 
might influence the clinical course of acute diarrheal dis-
eases. SCFAs have also been shown to be clinically im-
portant in transmissible gastroenteritis of swine  [8] , 
where animals infected with the virus develop acute en-
teritis with marked fluid loss. Young animals develop se-
vere diarrhea as their colonic mucosa is incapable of ab-
sorbing fluid, whereas colonic absorption in older infect-
ed animals is increased by about 6-fold over the controls. 
This compensatory response prevents severe diarrhea for 
the production of SCFAs.
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 Abstract
 Background: Partially hydrolyzed guar gum (PHGG) is a wa-
ter-soluble fiber if added to oral rehydration solution (ORS) 
and undergoes fermentation in the colon liberating short 
chain fatty acids (SCFAs). SCFAs potentiate the effect of ORS, 
reducing the severity of diarrhea.  Aim: To examine the effect 
of PHGG-added ORS in reducing the stool output and dura-
tion of diarrhea in adult cholera.  Methods: 195 male patients 
were studied in a randomized controlled trial: (a) 65 received 
ORS + 25 g PHGG; (b) 65 received ORS + 50 g PHGG, and (c) 
65 received ORS alone (control). Major outcomes were stool 
weight and duration of diarrhea.  Results: No significant dif-
ferences were found in mean  8 SD stool weight (g/kg b.w.) 
during the first and second 24 h. In the subgroup analysis 
(excluding very high purging patients, stool weight in the 
first 24 h was  1 10 kg), the stool weight (g/kg b.w.) was sig-
nificantly reduced in the first 24 h in both groups receiving 
PHGG (PHGG 25 g, 136  8 68 vs. PHGG 50 g, 144  8 49 vs. con-
trol, 176  8 43, p = 0.01).  Conclusion: PHGG-added ORS might 
have a beneficial effect in moderately purging adult cholera. 
However, further studies are warranted to confirm the pre-
liminary findings.  Copyright © 2008 S. Karger AG, Basel
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 Cholera is a disease of humans affecting the small in-
testine where fluid and electrolyte secretion is increased 
while their absorptions are decreased leading to profuse 
watery diarrhea. As the human colon has the capacity to 
absorb water and electrolytes  [9] , some compensation is 
expected to occur reducing the diarrheal loss. A recent 
study  [10] has shown that SCFAs stimulate sodium ab-
sorption in the colon, an effect that is independent of cy-
clic AMP. Additionally, SCFAs have been shown to in-
hibit cyclic AMP-mediated chloride secretion in the co-
lon  [11] . The SCFA-enhanced colonic absorption of water 
and electrolytes might be exploited in the treatment of 
acute diarrheal diseases. Oral rehydration therapy (ORT) 
has dramatically changed the management of acute diar-
rheal disease. However, efforts are continuing for im-
proving the efficacy of oral rehydration solution (ORS). 
Cereal-based ORSs have been shown to reduce the stool 
volume by about 30–40% in cholera compared to the 
WHO ORS  [12, 13] . It is possible that, at least in part, their 
effect on stool volume reduction might be attributed to 
SCFAs produced by fermentation of unabsorbed carbo-
hydrate, including dietary fiber in the colon.
 The colonic epithelial cells utilize SCFAs as a source of 
energy for their various metabolic activities  [14] . Human 
and animal colonocytes use butyrate in preference to glu-
cose, glutamine or ketone bodies as fuel sources  [14–17] . 
Thus, in contrast to small intestinal cells, colonic epithe-
lial cells derive the major part of their energy supply from 
the lumen rather than from blood. Depriving luminal 
nutrition of the mucosa has been found to induce fluid 
secretion  [18–20] . Recent clinical studies have demon-
strated the beneficial effect of amylase-resistant starch in 
the treatment of adult cholera  [21] and partially hydro-
lyzed guar gum (PHGG), a soluble fiber in the treatment 
of children with acute and persistent diarrhea  [22, 23] . 
Furthermore, several studies  [24–26] in the past have 
demonstrated that PHGG was effective in preventing di-
arrhea in patients with enteral nutrition after surgery and 
in critically ill patients. In this study, we evaluated the ef-
ficacy of PHGG-added ORS in reducing the severity and 
duration of adult cholera, a form of severe dehydrating 
diarrhea.
 Subjects and Methods
 The study was designed as a prospective, open, randomized, 
controlled clinical trial to evaluate the efficacy of PHGG-supple-
mented ORS in the treatment of severe cholera in adults in com-
parison with World Health Organization (WHO) recommended 
reduced osmolarity ORS (WHO ORS). The participants of this 
study were selected from among those attending the Dhaka Hos-
pital of ICDDRB from January 2004 to December 2006. The Eth-
ics Committee of the ICDDRB had approved the protocol, and 
written informed consent was obtained from each participant be-
fore their enrollment. Adult male patients aged 18–55 years with 
a history of watery diarrhea of  ! 24 h and severe dehydration, and 
their initial stool dark-field microscopy positive for  Vibrio chol-
erae, were eligible for participation in the study. Those with a his-
tory of chronic diarrhea, dysentery, renal or hepatic dysfunction, 
receiving antimicrobial or antidiarrheal drugs within 1 week pri-
or to admission, and refusal to provide written informed consent, 
were excluded from the study. After initial screening, patients 
were taken to the research ward of Dhaka Hospital, weighed, and 
placed on a cholera cot. A standard medical history, thorough 
physical examination including assessment of dehydration using 
modified WHO guidelines  [27] and vital signs were recorded in 
predesigned forms. The patient enrolment in the study was done 
from 06:  00 to 14:  00 h, 7 days a week. Prior to randomization, all 
patients were rehydrated with intravenous fluids containing poly-
electrolytes (Na 133, Cl 98, K 13, and acetate equivalent to 48 
mmol/l of bicarbonate) at a rate 100 ml/kg over 4–6 h, in addition 
an amount equivalent to their stool volume during this period.
 Randomization
 Eligible patients who completed rehydration (within 4–6 h of 
the observation period) were randomized in equal numbers to 
receive: (a) standard WHO ORS (Na 75, glucose 75, Cl 65, K 20, 
citrate 10 mmol/l, and osmolarity 245 mosm/l) + 25 g PHGG/l; 
(b) standard WHO ORS + 50 g PHGG/l, and (c) standard WHO 
ORS without PHGG. A randomization list was prepared for an 
intervention to control ratio 1:  1:1 using a random number table 
with permuted blocks of 12 and compiled by a statistician not in-
volved in the study. Serially numbered sealed identical envelopes 
were also prepared by the statistician containing the name of the 
allotted ORS. The envelopes were kept with the hospital’s phar-
macist. Upon enrolment, the requisition for ORS was given to the 
pharmacist indicating the serial number and patient’s name. The 
pharmacist prepared the ORS accordingly and supplied it to the 
study nurse indicating the patient’s name and serial number. The 
allocation of ORS could not be blinded because 50 g PHGG made 
a slight change in color of the solution, although the PHGG dis-
solves completely in ORS solution.
 Case Management
 Immediately after randomization (following intravenous re-
hydration), maintenance ORT was initiated using the assigned 
ORS solution. During the maintenance phase, patients consumed 
ORS solution according to need, but a minimum amount equal to 
watery/loose stool plus vomit. All study patients received oral 
doxycycline 300 mg as a single dose within 20 min of random-
ization. A standard local food was provided three times daily ac-
cording to the hospital practice: breakfast (bread, egg, sugar) at 
06:  30 h, lunch (boiled rice, meat/fish, lentil soup) at 12:  00 h and 
supper (food as at lunch) at 18:  00 h. Plain water was allowed as 
desired by the patients preferably after food. Intravenous fluid 
therapy was restarted in some patients developing signs of severe 
dehydration despite appropriate ORS therapy or/and for excessive 
vomiting that prevented successful oral therapy. Stools were col-
lected in a bucket placed underneath the cholera cot. All intakes 
(intravenous fluid, ORS, water) and outputs (stool, urine, vomit) 
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were measured and recorded for every 6-hour period of the study. 
Stool weight was measured with an electronic scale with a preci-
sion of 1 g (Sartorius, Göttingen, Germany). During the time of 
intake and output measurement, nurses also recorded the consis-
tency of stool (watery, soft or formed). Urine was separated in a 
urine collector and the volume measured with a calibrated glass 
cylinder. The weight of vomit was measured by collection in a 
preweighed bowl by subtracting that from the final weight of the 
bowl. The volume of ORS and plain water (ml) consumed by the 
patients were measured with a calibrated cylinder. Body weight 
was measured on admission (before initiation of intravenous 
therapy) at randomization (after intravenous rehydration) and 
every 6 h until discharged, using the same electronic scale.
 Laboratory Investigations
 Fresh stool samples were examined for the presence of  V. chol-
erae by dark-field microscopy during the 4- to 6-hour observation 
period. Stool samples were cultured for isolation and identifica-
tion of  V. cholerae, Salmonella and Shigella using the standard 
techniques. Peripheral venous blood samples were tested for he-
matocrit, total and differential white blood cells, blood urea ni-
trogen, creatinine, serum sodium, potassium, chloride, and bicar-
bonate at randomization and 24 h after randomization.
 All patients were observed closely until discharge. Resolution 
of diarrhea was defined if patients did not have stool for at least 
12 h or if they had two consecutive normal (formed) stools. Clin-
ical success was defined as cessation of diarrhea within 72 h from 
the start of study medication, and those with continued watery 
stool for  1 72 h were considered as clinical failure. Oral therapy 
failure was defined as reappearance of signs and/or symptoms of 
dehydration, requiring unscheduled intravenous fluid therapy. 
Duration (h) of diarrhea was calculated from the time of random-
ization to the last watery stool.
 Statistical Methods
 Sample size was determined based on a 30% expected reduc-
tion in the stool output in either of the two groups of patients to 
be treated with PHGG-added WHO ORS compared to the control 
group of patients who would be treated with the standard WHO 
ORS. In a recent study  [28] , the mean  8 SD stool (g/kg/1st 24 h) 
in cholera patients was observed to be 273  8 157. To demonstrate 
a 30% reduction in the stool volume, at 5% significance level with 
a power of 80%, 58 patients would be required in each of the three 
treatment groups. To adjust for a 10% dropout due to any reason, 
64 patients would be required to be enrolled in each group. In fact, 
65 patients in each group were studied.
 Data Analysis
 Statistical analyses were performed using SPSS PC+ (Version 
10). All statistical tests were two-tailed, performed at 5% level of 
significance. Continuous variables were compared using the 
analysis of variance (ANOVA) for within-group comparison and 
the post-hoc test was used for multiple comparisons. Categorical 
variables were compared with the   2  test or Fisher’s exact test as 
appropriate. Kaplan-Meier survival curves were constructed for 
the duration of diarrhea and compared by the log-rank test.
 Results
 In total, 367 patients were screened for eligibility. Of 
these, 195 were randomized for inclusion in the study: 65 
received WHO ORS + 25 g PHGG; 65 received WHO 
ORS + 50 g PHGG, and 65 received WHO ORS without 
PHGG (control). 174 patients were excluded because stool 
for dark-field examination at admission was negative for 
 V. cholerae  (159 patients) or refusal of informed consent 
(13 patients). Clinical characteristics at admission such as 
admission body weight, age of the patients, duration of 
diarrhea, duration of vomiting, number of stools before 
admission, number of vomits before admission, initial re-
quirement of intravenous fluid for rehydration and stool 
output during the screening period were comparable 
among the three treatment groups ( table 1 ). Comparison 
of stool output during the first and second 24 h after ran-
domization revealed no significant difference among the 
treatment groups. Similarly, intake of ORS during these 
 Table 1. Admission clinical characteristics of the study patients
 Variables  WHO ORS + PHGG
 (25 g) (n = 65) 
 WHO ORS + PHGG
 (50 g) (n = 65) 
 WHO ORS
 alone (n = 65) 
 p value 
 Age, years 29 8 10 29 8 8 29 8 9  0.27 
 Admission b.w., kg 45 8 6 46 8 5.6  46.5 8 7  0.51 
 Duration of diarrhea before admission, h 8.8 8 4 9 8 4.5 9 8 5  0.88 
 Number of stools before admission in the last 24 h 15 8 8 12 8 7 14 8 11  0.11 
 Duration of vomiting, h 6 8 4 6 8 4.4 6 8 3.7  0.81 
 Number of vomits before admission in the last 24 h 8 8 7 6 8 4 8 8 7  0.07 
 Initial intravenous fluid, ml/kg b.w.  159 8 33  159 8 35 150 8 27  0.21 
 Stool weight before randomization, g/kg b.w.  38 8 23 39 8 24 41 8 21  0.69 
 Values are mean  8 SD. b.w. = Body weight. 
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periods also showed no difference among the groups ( ta-
ble 2 ). When a subgroup analysis excluding very high 
purging (stool weight  1 10 kg during the first 24 h) pa-
tients was performed, the stool weight was significantly 
reduced in the groups receiving either ORS with 25 g 
PHGG/l (PHGG 25 g vs. control, p = 0.004) or ORS with 
50 g PHGG/l (PHGG 50 g vs. control, p = 0.003) com-
pared with the ORS without any PHGG ( table 3 ). Intake 
of ORS was also reduced in these patients; however, the 
differences were not statistically significant ( table 3 ). The 
mean duration of diarrhea was similar in the groups re-
ceiving WHO ORS with 25 g/l PHGG and WHO ORS 
without any PHGG; however, the mean duration was pro-
longed for a few hours in the group receiving WHO ORS 
with 50 g/l PHGG ( table 2 ). Although the difference was 
significant marginally for within-group comparison (p = 
0.04), multiple comparisons (post-hoc tests) failed to 
show a statistical significance (PHGG 25 g vs. control,
p = 0.97; PHGG 50 g vs. control, p = 0.09; PHGG 25 g vs. 
PHGG 50 g, p = 0.06). That might explain why compari-
son of survival analysis for duration of diarrhea ( fig. 1 ) 
demonstrated no statistically significant difference (p = 
0.12, log-rank test).
 Discussion
 The results of the study demonstrate that PHGG add-
ed to glucose-based ORS has shown beneficial effect in 
terms of reducing the stool output in patients with mod-
erate severity of diarrheal illness (after exclusion of very 
high purging patients, although it was not planned ini-
 Table 2. Comparison of outcome variables
 Variables  WHO ORS + PHGG
 (25 g) (n = 65) 
 WHO ORS + PHGG
 (50 g) (n = 5) 
 WHO ORS alone
 (control )  (n = 65) 
 p value 
 Stool weight, 1st 24 h, g/kg b.w 225 8 127 255 8 115  234 8 111  0.18 
 Stool weight, 2nd 24 h, g/kg b.w.  52 8 74 73 8 84 57 8 81  0.14 
 Urine volume, 1st 24 h, ml/kg b.w.  99 8 48 94 8 48  111 8 49  0.14 
 Urine volume, 2nd 24 h, ml/kg b.w.  120 8 38 119 8 45  109 8 33  0.58 
 ORS, 1st 24 h, ml/kg b.w.  282 8 115 304 8 119  286 8 80  0.46 
 ORS, 2nd 24 h, ml/kg b.w.  84 8 59 109 8 89  80 8 78  0.06 
 Water intake, 1st 24 h, ml/kg b.w.  62 8 33 63 8 26 61 8 32  0.81 
 Water intake, 2nd 24 h, ml/kg b.w.   84 8 49 90 8 33 71 8 42  0.25 
 Duration of diarrhea after randomization, h  31.44 8 11.1  36.9 8 14.3 32 8 12.5  0.04* 
 Patients who received unscheduled i.v. therapy  16/65 (25)  8/65 (12)  11/65 (17)  0.161 
 Values are mean  8 SD or numbers (%). b.w. = Body weight.
 * p value from ANOVA (comparison within three groups). Multiple comparisons (post-hoc test): PHGG 25 g vs. control, p = 0.97; 
PHGG 50 g vs. control, p = 0.09; PHGG 25 g vs. PHGG 50 g, p = 0.06. 
 Table 3. Comparison of outcome variables (subgroup analysis) excluding very high purging patients (1st 24 h stool weight >10 kg)
 WHO ORS + PHGG
 (25 g) (n = 34) 
 WHO ORS + PHGG
 (50 g) (n = 24) 
 WHO ORS alone
 (control) (n = 38) 
 p value 
 Stool weight, 1st 24 h, g/kg b.w.   136 8 68  144 8 49  176 8 43  0.01* 
 Stool weight, 2nd 24 h, g/kg b.w. 17 8 21 22 8 20 20 8 34  0.79 
 ORS, 1st 24 h, ml/kg b.w.  213 8 66  216 8 93  247 8 58  0.14 
 ORS, 2nd 24 h, ml/kg b.w. 28 8 38 29 8 36 26 8 39  0.79 
 Values are mean  8 SD. b.w. = Body weight.
 * p value  from ANOVA (within group comparison). Multiple comparisons (post-hoc tests): PHGG 25 g vs. control, p = 0.004; PHGG 
50 g vs. control, p = 0.003; PHGG 25 g vs. PHGG 50 g, p = 0.56. 
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tially). However, PHGG-containing ORS has failed to 
show a beneficial effect during treatment of severe adult 
cholera with very high stool output ( 1 10 kg in the first
24 h). This failure may be explained as: (a) the transit time 
in high purging cholera patients is very short, causing a 
washout effect leaving little time for fermentation; (b) the 
high purging patients required an increased amount of 
ORS including the fiber, and unabsorbed fiber added 
some weight to stool, and (c) in addition, the unferment-
ed fiber might hold some water which subsequently led to 
an increased stool weight. This mechanism would also be 
consistent with the failure of exhibiting a beneficial effect 
using ORS containing 50 g PHGG/l in the treatment of 
moderately purging patients that it could prolong diar-
rhea. Based on a similar hypothesis, Rama krishna et al. 
 [21] have carried out a study using glucose ORS supple-
mented with amylase-resistant starch in the treatment of 
adolescent and adult cholera. The addition of amylase-
resistant starch significantly reduced the duration of di-
arrhea and stool weight after 12 h; however, the severity 
of diarrhea in patients (mean stool weight  ! 10 kg) of that 
study was less than the present study, and the sample size 
was very small (16 patients in each group). Recently pub-
lished results of two studies  [22, 23] that reported a ben-
eficial effect of PHGG added to ORS or diet in the treat-
ment of non-cholera diarrhea in children also substanti-
ate the findings of our present study.
 In cholera, the reserve capacity of the colon is impaired 
 [7] . SCFAs are a potent stimulus for the colonic absorp-
tion of sodium and water from both the normal and se-
creting colon  [2, 29, 30] . The availability of SCFAs de-
pends on the fermentation of unabsorbed carbohydrate 
in the colon. Whether fermentation of unabsorbed PHGG 
was decreased due to a washout effect in very high purg-
ing patients cannot be answered from this study because 
measurement of luminal SCFAs was not performed. It 
has been demonstrated in an earlier study  [31] that PHGG 
added to liquid diet slows colonic transit time in healthy 
volunteers that might help in fermentation of PHGG for 
the prolongation of retaining time in the colon; however, 
it might not happen in very severe cholera. Another factor 
that is related to fermentation of unabsorbed carbohy-
drates in the colon is the availability of colonic flora; the 
washout effect in very high purging patients might have 
led to a decrease of colonic flora needed for fermentation 
of unabsorbed carbohydrate and formation of SCFAs.
 In spite of intake of large doses of PHGG and very high 
purging in adult cholera patients, no adverse effects such 
as vomiting, abdominal distension, etc. were noted in this 
study except prolongation of diarrhea for several hours 
with PHGG (50 g/l). As PHGG (25 g/l) in ORS has shown 
a better effect, further lowering the dose to 10–15 g/l 
might be tried in future studies to establish the optimum 
dose of PHGG.
 In conclusion, PHGG-supplemented ORS might be 
beneficial in moderately severe purging adult cholera pa-
tients. Further studies are warranted to confirm and sub-
stantiate the present study findings.
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